Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) shares hit a new 52-week low during trading on Thursday . The company traded as low as $0.72 and last traded at $0.72, with a volume of 321 shares changing hands. The stock had previously closed at $0.77.

A number of research analysts recently commented on the stock. Zacks Investment Research lowered shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 29th. Maxim Group reiterated a “hold” rating on shares of Sonoma Pharmaceuticals in a research note on Friday, November 9th. Finally, ValuEngine upgraded shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th.

The company has a market cap of $4.89 million, a P/E ratio of -0.24 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.84 and a current ratio of 3.80.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.02. The firm had revenue of $4.94 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 79.91% and a negative return on equity of 107.44%. Equities research analysts expect that Sonoma Pharmaceuticals Inc will post -2 earnings per share for the current year.

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC raised its holdings in Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,095 shares of the company’s stock after purchasing an additional 32,180 shares during the period. Renaissance Technologies LLC owned approximately 1.41% of Sonoma Pharmaceuticals worth $226,000 at the end of the most recent quarter. 11.93% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at

Sonoma Pharmaceuticals Company Profile (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Read More: Market Capitalization

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.